Drug intelligence / Profile preview

duraCAR-T71

Development stage: Preclinical
Lead developer: Protheragen
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

duraCAR-T71 is a preclinical-stage chimeric antigen receptor (CAR) T-cell therapy developed by Protheragen for the treatment of solid tumors. The therapy is engineered to specifically target Claudin 18.2 (CLDN18.2), a tight junction protein that is frequently overexpressed in gastric, pancreatic, and esophageal cancers while maintaining limited expression in normal tissues. duraCAR-T71 utilizes Protheragen's proprietary 'duraCAR' platform, which aims to enhance the persistence and anti-tumor efficacy of the CAR-T cells within the immunosuppressive tumor microenvironment.

Other names: duraCAR-T71duraCAR-T-71duraCAR-T 71

Targets

Claudin 18.2

Beyond the preview

Go deeper on duraCAR-T71.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on duraCAR-T71.

Explore the full profile